Consultation
We ask for feedback on proposals through public consultation, and take all consultation responses we receive into account before making our decisions. PHARMAC has published guidance for consumers on getting involved in our decisions, and this includes responses to consultation. You can download the document here (8 pages, 100 KB).
We welcome feedback from pharmaceutical suppliers, health professionals, health interest groups and the general public. This page includes consultations that are currently underway.
You can respond to consultation by writing to the address at the bottom of the consultation letter.
Rapid response
If you would like to make a rapid response to any of our consultations, 
click here. Remember to indicate which consultation proposal your comments relate to.
Search for previous consultations documents
- Funding proposal for clindamycin, sulphasalazine, cabergoline and medroxyprogesterone. Closes 12 November (3 pages, 163 KB) 29 Oct 2009
- Proposal for Arrow-Topiramate and Arrow-Alprazolam. Closes 4pm, 12 November (2 pages, 57 KB) 29 Oct 2009
- Proposal for sole supply arrangement for somatropin. Closes 12 November (3 pages, 179 KB) 29 Oct 2009
- Proposal relating to cyclosporin A, octreotide LAR and zoledronic acid. Closes 4pm, 12 November (2 pages, 154 KB) 29 Oct 2009
- Proposal relating to provisional agreement with API Consumer Brands Limited for the listings of various pharmaceuticals. Closes 5pm, 12 November (2 pages, 158 KB) 29 Oct 2009
- proposal for solifenacin (Vesicare), mesalazine (Asamax) and hydrocortisone preparations. Closes 4pm, 10 November (4 pages, 61 KB) 23 Oct 2009
- Proposal relating to tiotropium bromide. Closes 12 November (1 page, 102 KB) 22 Oct 2009
- Pharmaceutical Subsidy Eligibility and Delivery Review Discussion Paper October 2009 (8 pages, 200 KB) 16 Oct 2009
- Consultation on a proposal to reference price subsidised aromatase inhibitors. Closed (3 pages, 54 KB) 13 Oct 2009
- Consultation on proposed changes to Section H. Closed (2 pages, 73 KB) 13 Oct 2009
- Proposal regarding Sigma’s brands of furosemide tablets, ethambutol tablets and atopine eye drops. Closed (2 pages, 56 KB) 13 Oct 2009
- Proposal to widen access to tenofovir (Viread) for ‘treatment experienced’ patients with Hepatitis B infection. Closed (3 pages, 100 KB) 30 Sep 2009
- Proposed chemical additions to the 2009/10 Multi-product Tender (2 pages, 146 KB) 04 Sep 2009
- Proposal to fund Flamazine (silver sulphadiazine). Closed (1 page, 54 KB) 03 Sep 2009
- Proposal to fund hydrocortisone 1% (Pharmacy Health) 100 g. Closed (1 page, 106 KB) 02 Sep 2009
- Proposal to list Pfizer’s brands of heparinised saline and heparin sodium. Closed (1 page, 24 KB) 24 Aug 2009
Page updated on 01 Nov 2009
Linked documents
Having Your Say in our Decisions (8 pages, 100 KB)
Pharmaceutical Management Agency Having your say in our decisions PHARMAC’s decision-making PHARMAC is the Government agency that decides which medicines are funded for New Zealanders. We welcome input from people into our decision-making processes. There are a number of ways…
Funding proposal for clindamycin, sulphasalazine, cabergoline and medroxyprogesterone. Closes 12 November (3 pages, 163 KB)
29 October 2009 Funding proposal for clindamycin (Dalacin C), sulphasalazine (Salazopyrin), cabergoline (Dostinex) and medroxyprogesterone PHARMAC is seeking feedback on a proposal to amend the prices and subsidies for clindamycin (Dalacin C), cabergoline (Dostinex), sulphasalazine (Salazopyrin and Salazopyrin EN) and…
Proposal for Arrow-Topiramate and Arrow-Alprazolam. Closes 4pm, 12 November (2 pages, 57 KB)
29 October 2009 Proposal for Arrow-Topiramate and Arrow-Alprazolam PHARMAC is seeking feedback on a proposal to fund a new brand of topiramate tablets and reduce the price and subsidy for alprazolam through a provisional agreement with Arrow Pharmaceuticals (NZ) Limited.…
Proposal for sole supply arrangement for somatropin. Closes 12 November (3 pages, 179 KB)
29 October 2009 Proposal for sole supply arrangement for somatropin PHARMAC and Pfizer New Zealand Limited have entered into a provisional agreement for the ongoing funding of Genotropin, one of two brands of somatropin (also known as human growth hormone)…
Proposal relating to cyclosporin A, octreotide LAR and zoledronic acid. Closes 4pm, 12 November (2 pages, 154 KB)
29 October 2009 Proposal relating to cyclosporin A, octreotide LAR and zoledronic acid PHARMAC and Novartis New Zealand Limited have entered into a provisional agreement relating to the supply of Neoral (cyclosporin A 25 mg, 50 mg and 100 mg…
Proposal relating to provisional agreement with API Consumer Brands Limited for the listings of various pharmaceuticals. Closes 5pm, 12 November (2 pages, 158 KB)
29 October 2009 Proposal relating to provisional agreement with API Consumer Brands Limited for the listings of various pharmaceuticals on the Pharmaceutical Schedule PHARMAC is seeking feedback on a proposal involving cholecalciferol (Cal-d-Forte), codeine phosphate (PSM), dexamphetamine sulphate (PSM), glycerol…
proposal for solifenacin (Vesicare), mesalazine (Asamax) and hydrocortisone preparations. Closes 4pm, 10 November (4 pages, 61 KB)
23 October 2009 Funding proposal for solifenacin (Vesicare), mesalazine (Asamax) and hydrocortisone preparations PHARMAC is seeking feedback on a proposal to fund solifenacin (Vesicare) and mesalazine (Asamax), through a provisional agreement with CSL Biotherapies. The provisional agreement also includes price…
Proposal relating to tiotropium bromide. Closes 12 November (1 page, 102 KB)
22 October 2009 Proposal relating to tiotropium bromide PHARMAC is seeking feedback on a proposal relating to the listing of tiotropium bromide (Spiriva) inhalers in the Pharmaceutical Schedule. Spiriva (tiotropium bromide powder for inhalation, 18 μg per dose) is currently…
Pharmaceutical Subsidy Eligibility and Delivery Review Discussion Paper October 2009 (8 pages, 200 KB)
Pharmaceutical Subsidy Eligibility and Delivery Review Discussion Paper October 2009 Pharmaceutical Subsidy Eligibility and Delivery Review Introduction PHARMAC is reviewing the ways people receive subsidised pharmaceuticals in New Zealand. The review intends to answer the question: Once PHARMAC has made…
Consultation on a proposal to reference price subsidised aromatase inhibitors. Closed (3 pages, 54 KB)
13 October 2009 Consultation on a proposal to reference price subsidised aromatase inhibitors Summary of Proposal Following the announcement of the decision to award the Tender for letrozole (see notification letter dated 13 October 2009), PHARMAC now proposes to apply…
Consultation on proposed changes to Section H. Closed (2 pages, 73 KB)
12 October 2009 Proposal to change the format of Section H PHARMAC is seeking feedback on a proposal to change the format of Section H for Hospital Pharmaceuticals of the Pharmaceutical Schedule. In summary, this proposal would result in: 1.…
Proposal regarding Sigma’s brands of furosemide tablets, ethambutol tablets and atopine eye drops. Closed (2 pages, 56 KB)
13 October 2009 Proposal regarding Sigma’s brands of furosemide tablets (Urex Forte), ethambutol tablets (Myambutol) and atopine eye drops (Atropt) PHARMAC is seeking feedback on a provisional agreement with Sigma Pharmaceuticals (Australia) Pty Ltd regarding furosemide 500 mg tablets, ethambutol…
Proposal to widen access to tenofovir (Viread) for ‘treatment experienced’ patients with Hepatitis B infection. Closed (3 pages, 100 KB)
30 September 2009 Proposal to widen access to tenofovir (Viread) for ‘treatment experienced’ patients with Hepatitis B infection Summary of Proposal PHARMAC is seeking feedback on a proposal to widen access to tenofovir (Viread) for ‘treatment experienced’ Hepatitis B patients.…
Proposed chemical additions to the 2009/10 Multi-product Tender (2 pages, 146 KB)
4 September 2009 Proposed chemical additions to the 2009/10 Multi-product Tender PHARMAC has amended the list of chemicals it proposes to include in the Invitation to Tender 2009/10 by adding the chemicals set out below. The proposal to include these…
Proposal to fund Flamazine (silver sulphadiazine). Closed (1 page, 54 KB)
3 September 2009 Proposal to fund Flamazine (silver sulphadiazine) PHARMAC is seeking feedback on a proposal to fund a new brand of silver sulphadiazine 1% cream (Flamazine) on the Pharmaceutical Schedule. Silver sulphadiazine is a topical antibacterial used primarily as…
Proposal to fund hydrocortisone 1% (Pharmacy Health) 100 g. Closed (1 page, 106 KB)
2 September 2009 Proposal to fund hydrocortisone 1% (Pharmacy Health) 100 g PHARMAC is seeking feedback on a proposal to fund a new brand of hydrocortisone 1% cream (Pharmacy Health) in a pack size of 100 g on the Pharmaceutical…
Proposal to list Pfizer’s brands of heparinised saline and heparin sodium. Closed (1 page, 24 KB)
24 August 2009 Proposal to list Pfizer’s brands of heparinised saline and heparin sodium PHARMAC is seeking feedback on a proposal to list Pfizer New Zealand Limited’s brands of heparinised saline and heparin sodium from 1 October 2009. The proposal…
